Menu Search
Equities

Tasly Pharmaceutical Group Co Ltd

600535:SHH

Tasly Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)13.78
  • Today's Change-0.34 / -2.41%
  • Shares traded14.05m
  • 1 Year change-1.08%
  • Beta0.9517
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The 4 analysts offering 12 month price targets for Tasly Pharmaceutical Group Co Ltd have a median target of 16.65, with a high estimate of 19.56 and a low estimate of 15.30. The median estimate represents a 19.35% increase from the last price of 13.95.
High40.2%19.56
Med19.4%16.65
Low9.7%15.30

Dividends in CNY

In 2023, Tasly Pharmaceutical Group Co Ltd reported a dividend of 0.33 CNY, equaling last years dividend. The 6 analysts covering the company expect dividends of 0.35 CNY for the upcoming fiscal year, an increase of 4.55%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in CNY

On Aug 23, 2024, Tasly Pharmaceutical Group Co Ltd reported 2nd quarter 2024 earnings of 0.243 per share. This result exceeded the 0.21 expectation of the one analyst covering the company and under-performed last year's 2nd quarter results by 17.35%.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate+144.34%
Tasly Pharmaceutical Group Co Ltd reported annual 2023 earnings of 0.72 per share on Apr 15, 2024.
Average growth rate+61.31%
More ▼

Revenue history & estimates in CNY

of 2.49bn. This missed the 6.86bn estimate of the one analyst following the company.
Average growth rate+4.27%
Tasly Pharmaceutical Group Co., Ltd had revenues for the full year 2023 of 8.67bn. This was 0.94% above the prior year's results.
Average growth rate-15.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.